Cargando…

Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future

OBJECTIVE: To review the latest progress on the pathogenic mechanism and management of rheumatoid arthritis (RA)-associated coronary artery disease (CAD), and propose advice on future management optimization as well as prospects for research and development of new therapeutic regimen. DATA SOURCES:...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lun, Zhang, Yang, Zhang, Shu-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964948/
https://www.ncbi.nlm.nih.gov/pubmed/31855971
http://dx.doi.org/10.1097/CM9.0000000000000530
_version_ 1783488556829769728
author Wang, Lun
Zhang, Yang
Zhang, Shu-Yang
author_facet Wang, Lun
Zhang, Yang
Zhang, Shu-Yang
author_sort Wang, Lun
collection PubMed
description OBJECTIVE: To review the latest progress on the pathogenic mechanism and management of rheumatoid arthritis (RA)-associated coronary artery disease (CAD), and propose advice on future management optimization as well as prospects for research and development of new therapeutic regimen. DATA SOURCES: This study was based on data obtained from PubMed up to May 2019 using various search terms and their combinations, including coronary artery disease, myocardial ischemia, cardiovascular diseases, RA, rheumatic diseases, treatment, therapy, strategies, immunotherapy, inflammation, and anti-inflammation. STUDY SELECTION: All retrieved literature was scrutinized, most relevant articles about the pathogenic mechanism and clinical management, especially anti-inflammatory therapy of RA-associated CAD were reviewed. RESULTS: RA is an immune-mediated chronic inflammatory disease which has a great social disease burden. In addition to typical arthritic manifestations, RA also affects extra-articular tissues and organs, within which the involvement of the cardiovascular system, especially incorporating CAD, is the leading cause of death for patients with RA. Recently, numerous basic and clinical studies have been carried out on the mechanism of CAD development and progression under the inflammatory cascade of RA. The effect of traditional RA drugs on CAD risk management has been gradually clarified, and more emerging biologic agents are being explored and studied, which have also achieved satisfactory outcomes. Furthermore, with the success of the CANTOS clinical trial, novel anti-inflammatory therapy for the prevention of cardiovascular disease is believed to have a broad prospect. CONCLUSIONS: RA is an independent risk factor for CAD, which mainly results from the underlying inflammatory cascade; therefore, anti-inflammatory therapy, especially the emerging novel biologic drugs, is important for CAD management in patients with RA and may also be a promising approach among the general population.
format Online
Article
Text
id pubmed-6964948
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-69649482020-02-10 Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future Wang, Lun Zhang, Yang Zhang, Shu-Yang Chin Med J (Engl) Review Articles OBJECTIVE: To review the latest progress on the pathogenic mechanism and management of rheumatoid arthritis (RA)-associated coronary artery disease (CAD), and propose advice on future management optimization as well as prospects for research and development of new therapeutic regimen. DATA SOURCES: This study was based on data obtained from PubMed up to May 2019 using various search terms and their combinations, including coronary artery disease, myocardial ischemia, cardiovascular diseases, RA, rheumatic diseases, treatment, therapy, strategies, immunotherapy, inflammation, and anti-inflammation. STUDY SELECTION: All retrieved literature was scrutinized, most relevant articles about the pathogenic mechanism and clinical management, especially anti-inflammatory therapy of RA-associated CAD were reviewed. RESULTS: RA is an immune-mediated chronic inflammatory disease which has a great social disease burden. In addition to typical arthritic manifestations, RA also affects extra-articular tissues and organs, within which the involvement of the cardiovascular system, especially incorporating CAD, is the leading cause of death for patients with RA. Recently, numerous basic and clinical studies have been carried out on the mechanism of CAD development and progression under the inflammatory cascade of RA. The effect of traditional RA drugs on CAD risk management has been gradually clarified, and more emerging biologic agents are being explored and studied, which have also achieved satisfactory outcomes. Furthermore, with the success of the CANTOS clinical trial, novel anti-inflammatory therapy for the prevention of cardiovascular disease is believed to have a broad prospect. CONCLUSIONS: RA is an independent risk factor for CAD, which mainly results from the underlying inflammatory cascade; therefore, anti-inflammatory therapy, especially the emerging novel biologic drugs, is important for CAD management in patients with RA and may also be a promising approach among the general population. Wolters Kluwer Health 2019-12-20 2019-12-20 /pmc/articles/PMC6964948/ /pubmed/31855971 http://dx.doi.org/10.1097/CM9.0000000000000530 Text en Copyright © 2019 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Review Articles
Wang, Lun
Zhang, Yang
Zhang, Shu-Yang
Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future
title Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future
title_full Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future
title_fullStr Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future
title_full_unstemmed Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future
title_short Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future
title_sort immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964948/
https://www.ncbi.nlm.nih.gov/pubmed/31855971
http://dx.doi.org/10.1097/CM9.0000000000000530
work_keys_str_mv AT wanglun immunotherapyfortherheumatoidarthritisassociatedcoronaryarterydiseasepromiseandfuture
AT zhangyang immunotherapyfortherheumatoidarthritisassociatedcoronaryarterydiseasepromiseandfuture
AT zhangshuyang immunotherapyfortherheumatoidarthritisassociatedcoronaryarterydiseasepromiseandfuture